Form 4: Alignment Healthcare CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Alignment Healthcare CEO John E. Kao sold 180,000 shares of common stock for a weighted-average price of $17.286 per share under a pre-arranged 10b5-1 plan.
Summary
- John E. Kao, Chief Executive Officer and Director of Alignment Healthcare, Inc. (ALHC), reported a sale of common stock.
- The transaction involved the disposition of 180,000 shares of Alignment Healthcare common stock.
- The sale occurred on October 10, 2025, under a Rule 10b5-1 trading plan adopted on March 12, 2025.
- The shares were sold at a weighted-average price of $17.286 per share, with individual transaction prices ranging from $16.97 to $17.60.
- Following the reported transaction, Mr. Kao beneficially owns 2,706,726 shares indirectly through the JEK Trust and 2,839,942 shares directly.
- On September 25, 2025, 1,693,626 shares previously held directly by Mr. Kao were transferred to the JEK Trust, dated February 8, 2021, for which Mr. Kao serves as trustee.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While an insider sale by a CEO can sometimes be viewed negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns, as these plans are typically set up for personal financial planning rather than as a signal about the company's immediate prospects.
Negatives
- The sale of 180,000 shares by the Chief Executive Officer could be perceived negatively by some investors, although it was executed under a pre-arranged 10b5-1 plan.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects a planned sale by a key executive in the healthcare sector.
Related Party Transactions
- On September 25, 2025, 1,693,626 shares held directly by Mr. Kao were transferred to the JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee. This represents a change in the form of beneficial ownership involving a related entity.
Stakeholder Impact
- Shareholders may observe the CEO's sale of shares, which, despite being pre-planned, could lead to questions about management's confidence or personal financial strategy. However, the 10b5-1 plan context generally reduces the perceived negative signal.
Key Dates
| Date | Description |
|---|---|
| 02/08/2021 | Date of JEK Trust establishment. |
| 03/12/2025 | Date of Rule 10b5-1 plan adoption by John E. Kao. |
| 09/25/2025 | Transfer of 1,693,626 shares from direct ownership to JEK Trust. |
| 10/10/2025 | Date of common stock transaction (sale of 180,000 shares). |
| 10/14/2025 | Signature date of the Form 4 filing. |
Recommendation
holdThe filing details a pre-planned insider sale by the CEO under a Rule 10b5-1 plan. While insider sales can sometimes be a negative signal, the pre-arranged nature suggests personal financial planning rather than a reaction to new, adverse company information. This single transaction, therefore, does not fundamentally alter the investment thesis for Alignment Healthcare, warranting a 'hold' recommendation for existing investors.
Keywords
Alignment Healthcare, ALHC, John E. Kao, Insider Sale, Form 4, 10b5-1 Plan, CEO, Common Stock, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.